Clinical Trial Update: Early Results Published for DM1 Investigational Therapy

Pharmaceutical company PepGen has published preliminary results from the first phase of its FREEDOM2-DM1 clinical trial, which is investigating a potential new therapy for people living with myotonic dystrophy type 1 (DM1).